Want to see LBRX full AI Analyst Report?
LBRX Stock Chart & Stats
$47.10
--
Market closed
$47.10
--
Day’s Range― - ―
52-Week Range$13.36 - $50.16
Previous CloseN/A
VolumeN/A
Average Volume (3M)353.82K
Market Cap
$1.59B
Enterprise Value$655.55
Total Cash (Recent Filing)$327.79M
Total Debt (Recent Filing)$5.22M
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Nov 05, 2026EPS Estimate
-1.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.97
Shares Outstanding32,259,174
10 Day Avg. Volume281,686
30 Day Avg. Volume353,825
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)1.87
Price to Sales (P/S)0.00
P/FCF Ratio-15.97
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$56.57Price Target Upside20.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-5.36
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Major Financing Strengthens LiquidityThe $150M financing materially improves funding capacity for late-stage trials and broader indications. It reduces near-term liquidity pressure and supports continued execution, although the equity-linked structure may still create dilution for existing shareholders.
Accelerated Phase 3 Development TimelineFaster enrollment shortens the path to a pivotal clinical readout for LB-102, potentially enabling earlier regulatory planning and commercial preparation. The trial remains the central value driver, while prior positive Phase 2 data supports the development rationale.
Stronger Balance Sheet And Low LeverageThe shift to strongly positive equity and very low debt improves solvency and financial flexibility compared with prior years. This stronger capital base should help fund development programs and reduce balance-sheet constraints during ongoing clinical investment.
Bears Say
No Revenue And Persistent LossesThe company has no demonstrated commercial revenue base and remains materially unprofitable. Until a product is approved and launched, operating costs will continue without recurring sales support, leaving results dependent on clinical progress and access to capital.
Ongoing Operating Cash BurnPersistent negative operating and free cash flow shows that the business cannot currently fund operations internally. Continued clinical development will require substantial spending, making future financing needs and potential shareholder dilution durable risks until revenue ramps.
History Of Balance-sheet StressAlthough the 2025 balance sheet improved, prior negative equity demonstrates a history of financial stress and dependence on external funding. This record highlights the risk that additional capital may be needed if trials take longer, costs rise, or development results disappoint.
LB Pharmaceuticals, Inc. News
LBRX FAQ
What was LB Pharmaceuticals, Inc.’s price range in the past 12 months?
LB Pharmaceuticals, Inc. lowest stock price was $13.36 and its highest was $50.16 in the past 12 months.
What is LB Pharmaceuticals, Inc.’s market cap?
LB Pharmaceuticals, Inc.’s market cap is $1.59B.
When is LB Pharmaceuticals, Inc.’s upcoming earnings report date?
LB Pharmaceuticals, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 60 days.
How were LB Pharmaceuticals, Inc.’s earnings last quarter?
LB Pharmaceuticals, Inc. released its earnings results on Aug 11, 2026. The company reported -$1.71 earnings per share for the quarter, missing the consensus estimate of -$0.804 by -$0.906.
Is LB Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts LB Pharmaceuticals, Inc.’s price is currently Undervalued.
Does LB Pharmaceuticals, Inc. pay dividends?
LB Pharmaceuticals, Inc. does not currently pay dividends.
What is LB Pharmaceuticals, Inc.’s EPS estimate?
LB Pharmaceuticals, Inc.’s EPS estimate is -1.61.
How many shares outstanding does LB Pharmaceuticals, Inc. have?
LB Pharmaceuticals, Inc. has 32,259,174 shares outstanding.
What happened to LB Pharmaceuticals, Inc.’s price movement after its last earnings report?
LB Pharmaceuticals, Inc. reported an EPS of -$1.71 in its last earnings report, missing expectations of -$0.804. Following the earnings report the stock price went down -1.134%.
Which hedge fund is a major shareholder of LB Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in LBRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
LB Pharmaceuticals, Inc. Stock Smart Score
Learn more about TipRanks Smart Score
Company Description
LB Pharmaceuticals, Inc.
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
LBRX Stock 12 Month Forecast
Average Price Target
$56.57
▲(20.11% Upside)
Technical Analysis
Ownership Overview
21.88% Insiders
11.96% Mutual Funds
8.48% Other Institutional Investors
49.73% Public Companies and
Individual Investors